Related Experiment Videos
[Safety and reactogenicity of a group-A meningoccal polysaccharide vaccine for children 5 to 14]
Insights
This study found the group A meningococcal polysaccharide vaccine safe and mildly reactogenic in children aged 5-14 years. Minor blood count shifts and mild fever were observed, indicating its suitability for immunization.
Area of Science:
- Immunology
- Vaccinology
- Pediatric Infectious Diseases
Background:
- Meningococcal disease remains a significant public health concern, necessitating effective vaccination strategies.
- Group A meningococcal polysaccharide vaccines are crucial for preventing invasive meningococcal disease.
Purpose of the Study:
- To evaluate the safety and reactogenicity of a novel group A meningococcal polysaccharide vaccine.
- To assess the vaccine's impact on hematological parameters and local/systemic reactions in children.
Main Methods:
- The study involved administering the group A meningococcal polysaccharide vaccine to children aged 5-14 years.
- Safety and reactogenicity were assessed through monitoring blood counts, body temperature, and local injection site reactions.
Main Results:
- The vaccine was characterized as safe and demonstrated mild reactogenicity in the studied pediatric population.
- Observed hematological shifts remained within physiological limits, and local reactions (hyperemia) were insignificant.
- Some children aged 5-8 years experienced transient subfebrile temperatures for up to 2 days post-vaccination.
Conclusions:
- The group A meningococcal polysaccharide vaccine is safe and well-tolerated in children aged 5-14 years.
- Further determination of the optimal vaccination dose will consider immunological activity alongside safety data.
Abstract:
The safety and reactogenicity of group A meningococcal polysaccharide vaccine prepared at the G. N. Gabrichevsky Research Institute for Epidemiology and Microbiology (Moscow) and intended for the immunization of children aged 5-14 years were studied. The data obtained in this study made it possible to characterize the preparation as safe and mildly reactogenic. Shifts in the blood formula registered 24 hours after the injection of the vaccine remained within the limits of physiological fluctuations. Subfebrile temperature persisting for 2 days was registered in some of the children aged 5-8 years. Local reaction in the form of hyperemia at the site of injection was insignificant. The optimum vaccination dose will be determined on the basis of the whole complex of the data presented in this work, as well as the data on the immunological activity of the preparation.